Page 36 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Al-Khawaga and Abdelalim Stem Cell Research & Therapy (2020) 11:437 Page 17 of 33

Recruitment status Recruiting Recruiting not Active, recruiting Recruiting yet Not recruiting yet Not recruiting yet Not recruiting Recruiting Recruiting yet Not recruiting yet Not recruiting Recruiting

Country China Turkey China USA USA Colombia Germany China Spain Canada USA USA

placebo or care of treatment care

group (saline) (saline) care of (saline) Hydroxychloroquine, lopinavir/ritonavir and therapy) intervention. standard + supportive
Control Placebo Placebo Oseltamivir Standard Placebo azithromycin (standard No N.A Placebo N.A. Conventional |+placebo Best

Estimated enrollment each (15 30 group) each (10 30 group) 60 each (12 24 group) each (50 100 group) 40 each (20 40 group). 9 each to (15 30 group) 9 70 (1:1 86 randomization ratio)

(Continued) apart), (1 week 3, 0, days apart, 4 days 7, 3, 0, days not at 25 × 10 6 at 50 × 10 6 at 90 × 10 6 in cells 7 and

patients administration 1 × 10 6 /kg on cells/kg 1 × 10 6 /kg, IV cells, at cells IV route cells/kg, IV cells/kg, doses three doses three doses three 1.0 × 10 6/ /kg treatment CM+ 100 ml 4, 1, days

COVID-19 of route of doses 3 × 10 6 of of doses 100 × 10 6 of 1.0 × 10 8 of 50 × 10 6 , of 10 6 or 5, 1 × 10 6 1: group 2: group 3: group IV 1: group Conventional 2: group treatment on infusions

treat and doses IV single IV + Oseltamivir doses doses IV 10, doses 3, of doses, Intervention IV 3 1, Intervention IV 3 1, Intervention 3, 1, Intervention CM+ Intervention conventional
to Dose One-two IV Three 6, and Four Two Four and Two N.A. Doses specified Two 0, day 0, day 0, day 100 ml CYNK-001
exosomes Intervention/ UC- UC- UC- + UC- add- as + therapy of AT- WJ- stand- + care BM- cell- cells M + of WJ- WJ- and killer cells from

MSC-derived Phase treatment Allogeneic MSCs Allogeneic MSCs Allogeneic MSCs oseltamivir Allogeneic MSCs on standard care Allogeneic MSCs Allogeneic MSCs of ard Allogeneic MSCs Human embryonic stem derived (CAStem) WJ-MSCs standard care BM-MSCs (undefined source) Allogeneic MSCs MSC-CM Natural (NK) derived human placental

and 1/2 1/2 1 1/2 2 1/2 2 1/2 1/2 1 1/2 1/2
MSCs masking masking open-label masking as-

using masking RCT masking assignment, parallel Open-label non- sequential open-label masking

trials design triple* Interventional, Open-label parallel blinded, quadruple* quadruple* Interventional, quadruple* Interventional, double* open-label
clinical Study RCT, quadruple* RCT, RCT, double RCT, RCT, Randomized, assignment, RCT, randomized, signment, RCT, RCT,

Ongoing

3 trial NCT04339660 NCT04392778 NCT04371601 NCT04355728 NCT04362189 NCT04390152 NCT04377334 NCT04331613 NCT04390139 NCT04400032 NCT04398303 NCT04365101
Table Clinical identifier